Fulvic Acid, Trace Minerals, and Kidney Health. What the Evidence Supports (and What It Doesn't).

Quick answer: There is no randomized controlled trial testing shilajit for kidney health outcomes. That is the honest starting point, and it matters. What does exist is a coherent body of research about what fulvic acid does to mineral balance, heavy metal handling, and oxidative stress. All three are relevant to how the kidneys function. This article covers what the evidence actually supports, where it stops, and why the combination of chelating chemistry and mineral delivery makes fulvic acid relevant to this conversation in the first place.

What the kidneys do, and why minerals matter

The kidneys filter roughly 200 liters of blood every day. Their job is to regulate the concentration of minerals in the body, remove waste products, control fluid balance, and manage the excretion of compounds the body has processed and no longer needs.

Mineral regulation is central to that work. The kidneys manage the balance of sodium, potassium, magnesium, calcium, phosphate, and dozens of trace elements, holding each within the narrow range the body requires. When mineral intake is too low, the kidneys conserve. When it is too high, they excrete. When minerals arrive in forms the body cannot use efficiently, the kidneys work harder to accomplish the same task.

This is the relevant context for why fulvic acid and the trace mineral matrix in shilajit appear in discussions of kidney health. It is not that shilajit treats the kidneys. It is that what shilajit does to mineral delivery, heavy metal binding, and oxidative stress touches three things the kidneys are directly involved in managing every day.

What fulvic acid does as a mineral carrier

Fulvic acid is a naturally occurring organic acid found in soil, peat, and geological deposits like shilajit. Its chemical structure makes it effective as a mineral chelate, a molecule that forms a stable complex with metal ions and carries them.

In the gut, this chelating property matters for bioavailability. Minerals that arrive bound to fulvic acid are escorted across the intestinal membrane more efficiently than the same minerals in isolated salt or oxide form. Fulvic acid also improves cellular membrane permeability, which helps the minerals that reach the bloodstream actually get into cells where they are needed rather than being excreted before they are used.

For kidney function, the relevance of this carrier property runs in two directions. Well-absorbed minerals arrive in forms that are put to use, which means less of the excess processing load the kidneys take on when minerals are delivered in poorly absorbed forms. And fulvic acid's chelating structure means it can bind to certain compounds the body is working to clear, a property that connects directly to the heavy metals question.

The heavy metals question, answered honestly

Shilajit is a geological resin, and the first thing anyone should ask about a geological substance is whether it carries heavy metals from the deposit it came from. This is a fair question, not a fringe concern, and the honest answer involves two things at once.

First, an ICP-MS analysis of commercial shilajit products published in 2021 found that all tested samples met FDA limits for arsenic, mercury, lead, and cadmium. A 2025 review on thallium content found that the Saravan, Iran deposit showed elevated thallium at 0.226 micrograms per gram, while the Indian deposit measured 0.007. The Altai mountains, where Optimum shilajit comes from, represent a different geological profile from those high-concern origin points. Source geography and processing method are the variables that matter, which is why third-party lab testing is the relevant standard rather than a blanket concern about geological resins.

Second, a 2024 review in PubMed documented what resolves the apparent paradox about shilajit and heavy metals. The humic substances that make up shilajit, of which fulvic acid is one major class, are well-documented chelating agents that actively bind and detoxify approximately 12 heavy metals in the gut and bloodstream. The same compound that raises the initial concern is also the compound whose chemical structure allows it to bind those metals and escort them out. This is not a claim that shilajit clears heavy metals or treats heavy metal toxicity. It is the chemical context for why purified, tested shilajit and heavy metal risk are more nuanced than the surface concern suggests.

Oxidative stress and kidney function

Oxidative stress is one of the primary drivers of kidney tissue damage in aging kidneys and in kidneys under metabolic load. The kidneys are high-energy organs that generate significant oxidative byproducts as part of their filtering work. When the body's antioxidant capacity falls, kidneys are among the tissues that accumulate that burden.

Fulvic acid has been studied specifically for its antioxidant properties. A 2018 review by Winkler and Ghosh published in the Journal of Diabetes Research found that fulvic acid modulates the immune response, reduces TNF-alpha, and improves oxidative stress markers across multiple research models. The review identified particular relevance for conditions associated with chronic inflammation and oxidative burden.

This matters for kidney health not as a direct treatment but as a mechanistic connection. Reducing the oxidative load on a tissue that generates a lot of it is relevant to how that tissue functions over time. The fulvic acid research on oxidative stress is not kidney-specific, but the mechanism applies there as it does to other tissues running under sustained oxidative conditions.

After menopause, oxidative stress rises as estrogen's antioxidant support falls. The kidneys are not insulated from that shift. The fulvic acid in shilajit addressing oxidative stress is relevant to that picture, even without a study that was designed specifically around kidney outcomes.

What the animal safety studies found for kidney tissue

The most direct kidney-relevant safety data comes from a 91-day high-dose study by Velmurugan and colleagues published in 2012. Rats received shilajit at doses up to 5000 milligrams per kilogram of body weight per day for 91 days. That is a dose far beyond any human therapeutic range. The researchers examined organ histology, blood chemistry, and functional markers at the end of the study period.

Kidney histology was normal. Organ weights were stable. Iron levels, which the kidneys regulate, were within normal ranges. No organ toxicity was found at any of the tested doses.

This does not mean dose is irrelevant or that every form of shilajit is safe. It means that in a controlled safety study at extreme doses over an extended period, kidney tissue showed no sign of damage or dysfunction. That is the most direct piece of kidney-tissue data in the available research.

What the evidence does not show

This section matters as much as anything else in the article, because the search results around shilajit and kidney health often imply more than the research supports.

There is no randomized controlled trial in humans on shilajit and kidney stones. There is no human study on shilajit and chronic kidney disease. There is no evidence from human trials that shilajit prevents kidney stones, improves glomerular filtration rate, treats any kidney condition, or produces measurable changes in kidney function markers in people.

The research that exists shows what fulvic acid does to minerals and heavy metals, what the oxidative stress markers look like after fulvic acid exposure, and what kidney histology looks like after high-dose shilajit in animals over 91 days. That is a reasonable foundation for understanding how these mechanisms relate to kidney function. It is not evidence for kidney outcomes in human trials, because those trials have not been done.

If a shilajit product is making explicit kidney health claims backed by human clinical trials, it is claiming more than the published literature supports.

Safety

Across every human clinical study ever done on shilajit, zero serious adverse events have been reported. A 90-day open-label study in men noted no liver or kidney changes in standard blood panels over that period. The 91-day animal safety study confirmed normal kidney histology at doses far above the human range.

Optimum shilajit comes from the Altai mountains, purified and third-party lab tested every batch for heavy metals and mycotoxins. It comes as a box of tablets from a small, family-owned company out of Florida, and a real person answers when you reach out. The lab results are available to read.

What this means

The connection between fulvic acid and kidney health is real but indirect. Fulvic acid is a genuine mineral carrier with genuine chelating properties and a genuine oxidative stress effect. Those three things are relevant to how the kidneys do their work every day. The animal safety studies show normal kidney tissue after extended high-dose exposure. The human safety record shows zero serious adverse events across all studies.

What does not exist is a clinical trial on kidney outcomes, and the honest accounting of the evidence has to say so. The mineral balance argument, the heavy metal binding argument, and the oxidative stress argument are each grounded in real research. A kidney outcome claim is not, because that trial has not been run.

That distinction is the one this article was built to make clear.

If you are looking for the shilajit with the broadest trace mineral profile, you can find Optimum Shilajit here: https://www.liveoptimum.co/products/optimum-shilajit

References

1. Heavy metals and shilajit: review of geological variability and humic substance chelation. PubMed. 2024. https://pubmed.ncbi.nlm.nih.gov/38393486/
2. ICP-MS quantification of heavy metals in commercial shilajit supplements. PubMed. 2021. https://pubmed.ncbi.nlm.nih.gov/34800280/
3. Thallium content in shilajit supplements by source geography. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11743217/
4. Winkler J, Ghosh S. Therapeutic potential of fulvic acid in chronic inflammatory diseases and diabetes. J Diabetes Res. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6151376/
5. Velmurugan C et al. Evaluation of safety profile of black shilajit after 91 days repeated administration in rats. Asian Pac J Trop Biomed. 2012. https://pmc.ncbi.nlm.nih.gov/articles/PMC3609271/
6. Biswas TK et al. Clinical evaluation of spermatogenic activity of the root extract of Ashwagandha in oligospermic males. Asian J Androl. 2010. https://pubmed.ncbi.nlm.nih.gov/20078516/
7. Stohs SJ et al. A review on the safety and efficacy of shilajit. Phytother Res. 2014. https://pubmed.ncbi.nlm.nih.gov/23733436/
8. Agarwal SP et al. Shilajit: a review. Phytother Res. 2007. https://pubmed.ncbi.nlm.nih.gov/17295385/